iTeos Therapeutics to Present Preclinical Data for its Anti-TIGIT antibody, EOS-448, at the AACR II Virtual Annual Meeting 2020
June 15, 2020 07:00 ET
|
iTeos Therapeutics SA
iTeos Therapeutics to Present Preclinical Data for its Anti-TIGIT antibody, EOS-448, at the AACR II Virtual Annual Meeting 2020 Cambridge, MA and Gosselies, Belgium – June 15,...
iTeos Therapeutics Strengthens Leadership Team
June 09, 2020 07:00 ET
|
iTeos Therapeutics SA
iTeos Therapeutics Strengthens Leadership Team Matthew Gall joins as Chief Financial OfficerDr. Yvonne McGrath joins as Vice President of R&DPhilippe Brantegem joins as Vice President of Human...
iTeos Therapeutics Appoints Ann D. Rhoads to Board of Directors
June 01, 2020 07:00 ET
|
iTeos Therapeutics SA
iTeos Therapeutics Appoints Ann D. Rhoads to Board of Directors Cambridge, MA and Gosselies, Belgium – June 1, 2020 – iTeos Therapeutics, a clinical-stage biopharmaceutical company pioneering the...
iTeos Therapeutics to Present at UBS Global Healthcare Conference
May 13, 2019 08:00 ET
|
iTeos Therapeutics SA
iTeos Therapeutics to Present at UBS Global Healthcare Conference Gosselies, Belgium and Cambridge, MA – May 13, 2019 – iTeos Therapeutics SA, a privately-held biotechnology company developing novel...
iTeos Therapeutics to Present Data at 2018 SITC Annual Meeting
November 06, 2018 08:00 ET
|
iTeos Therapeutics SA
iTeos Therapeutics to Present Data at 2018 SITC Annual Meeting Gosselies, Belgium – November 6, 2018 – iTeos Therapeutics SA, a biotechnology company developing novel cancer immunotherapies, today...